|
CN109395082A
(zh)
*
|
2000-05-19 |
2019-03-01 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
AU2004217434B2
(en)
*
|
2000-12-08 |
2010-08-26 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US7408041B2
(en)
*
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
WO2002059280A2
(en)
*
|
2000-12-08 |
2002-08-01 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
|
WO2003062375A2
(en)
*
|
2001-12-19 |
2003-07-31 |
Genentech, Inc. |
Stabilizing polypeptides which have been exposed to urea
|
|
AU2003210549A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Chiron Corporation |
Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
|
|
EP1531850B1
(en)
*
|
2002-06-07 |
2012-02-22 |
ZymoGenetics, Inc. |
Use of IL-21 and monoclonal antibody for treating solid cancers
|
|
AU2003280442B2
(en)
|
2002-07-01 |
2009-02-05 |
Wilex Ag |
Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
|
|
EP1758610B1
(en)
*
|
2004-05-20 |
2012-07-04 |
ZymoGenetics, Inc. |
Methods of treating cancer using il-21 and monoclonal antibody therapy
|
|
KR20130089280A
(ko)
|
2005-01-21 |
2013-08-09 |
제넨테크, 인크. |
Ｈｅｒ 항체의 고정 용량 투여법
|
|
DE602006021142D1
(de)
*
|
2005-02-03 |
2011-05-19 |
Gen Hospital Corp |
Verfahren zur behandlung von gefitinib-resistentem krebs
|
|
ES2440481T3
(es)
*
|
2005-02-23 |
2014-01-29 |
Genentech, Inc. |
Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
|
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US8105768B2
(en)
|
2005-03-09 |
2012-01-31 |
Abbott Laboratories |
Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
PE20070763A1
(es)
*
|
2005-11-04 |
2007-08-08 |
Wyeth Corp |
COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
|
|
US20070111906A1
(en)
*
|
2005-11-12 |
2007-05-17 |
Milner Jeffrey L |
Relatively low viscosity transmission fluids
|
|
PL2463305T3
(pl)
*
|
2006-01-12 |
2017-02-28 |
Alexion Pharmaceuticals, Inc. |
Przeciwciała przeciw OX-2/CD200 i ich zastosowania
|
|
DE102006011507A1
(de)
*
|
2006-03-14 |
2007-09-20 |
Lts Lohmann Therapie-Systeme Ag |
Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
|
|
CN101522717A
(zh)
*
|
2006-08-04 |
2009-09-02 |
阿斯利康(瑞典)有限公司 |
针对ErbB2的人抗体
|
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
AU2008279618B2
(en)
*
|
2007-07-25 |
2014-05-22 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
ES2692769T3
(es)
|
2008-06-17 |
2018-12-05 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
|
CN109464445A
(zh)
|
2008-08-04 |
2019-03-15 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
JP2012507299A
(ja)
|
2008-10-31 |
2012-03-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｌｉｇｈｔ標的分子およびその使用
|
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
|
LT3000467T
(lt)
|
2009-04-06 |
2023-04-11 |
Wyeth Llc |
Krūties vėžio gydymo schema naudojant neratinibą
|
|
US20120121586A1
(en)
|
2009-05-29 |
2012-05-17 |
Astrid Kiermaier |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
NZ601111A
(en)
|
2010-01-11 |
2014-07-25 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
|
NZ601580A
(en)
|
2010-02-11 |
2014-11-28 |
Alexion Pharma Inc |
Therapeutic methods using anti-cd200 antibodies
|
|
BR112012017405A2
(pt)
|
2010-02-18 |
2018-08-14 |
Genentech Inc |
método para aumentar o tempo até a recorrência do tumor em paciente com câncer
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
WO2014083178A1
(en)
|
2012-11-30 |
2014-06-05 |
F. Hoffmann-La Roche Ag |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
KR101453462B1
(ko)
*
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
CA2940252C
(en)
|
2014-03-11 |
2022-10-18 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
HUE054529T2
(hu)
|
2014-03-11 |
2021-09-28 |
Molecular Templates Inc |
Amino-terminális proximális Shiga toxin A alegység effektor régiókat és sejtcélzó immunglobulin-típusú kötõrégiókat tartalmazó proteinek, amelyek képesek CD38 specifikus kötésére
|
|
SG11201608192SA
(en)
|
2014-04-11 |
2016-10-28 |
Medimmune Llc |
Bispecific her2 antibodies
|
|
US9586056B2
(en)
|
2014-07-03 |
2017-03-07 |
Haniva Llc |
Combination therapy for treating cancer and method for treating cancer using a combination therapy
|
|
WO2016052971A1
(ko)
*
|
2014-09-30 |
2016-04-07 |
가톨릭대학교 산학협력단 |
유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법
|
|
CN114656573B
(zh)
|
2015-05-30 |
2024-09-27 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
EP3325510A2
(en)
|
2015-07-26 |
2018-05-30 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
WO2018140427A1
(en)
|
2017-01-25 |
2018-08-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
SG11201909949XA
(en)
|
2017-05-24 |
2019-11-28 |
Pandion Therapeutics Inc |
Targeted immunotolerance
|
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
US12139533B2
(en)
|
2017-12-20 |
2024-11-12 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-CD200 antibodies
|
|
WO2019204272A1
(en)
|
2018-04-17 |
2019-10-24 |
Molecular Templates, Inc. |
Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
|
|
KR20220035333A
(ko)
|
2019-05-20 |
2022-03-22 |
팬디온 오퍼레이션스, 인코포레이티드 |
Madcam 표적 면역관용
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|